{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:48:18Z","timestamp":1776984498297,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of tamsulosin vs the combination of tamsulosin and tadalafil in male lower urinary tract symptoms (LUTS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      This was a double\u2010blinded, parallel\u2010arm randomised controlled trial. Men aged &gt;45\u00a0years with moderate LUTS and a maximum urinary flow rate (Q\n                      <jats:sub>max<\/jats:sub>\n                      ) of 5\u201315\u00a0mL\/s were included. One arm received 0.4\u00a0mg tamsulosin only (Group\u2010A), while the second received 5\u00a0mg tadalafil with tamsulosin (Group\u2010B). The primary outcome was the International Prostate Symptom Score (IPSS). Secondary outcomes were IPSS quality of life (QoL) score, five\u2010item version of the International Index of Erectile Function (IIEF\u20105) score, Q\n                      <jats:sub>max<\/jats:sub>\n                      , and post\u2010void residual urine (PVR). Block randomisation was used. Placebo was used for blinding and allocation concealment. Intention\u2010to\u2010treat analysis was used for outcome measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 183 men screened, 140 were randomised (71 in Group\u2010A, 69 in Group\u2010B); 116 (82.85%) (61 in Group\u2010A, 55 in Group\u2010B) completed the study. Baseline characteristics were comparable. The improvements in the IPSS, IPSS QoL score, IIEF score and Q\n                      <jats:sub>max<\/jats:sub>\n                      were \u22121.69 (95% confidence interval [CI] \u22121.4 to \u22122.0), \u22120.70 (95% CI \u22120.60 to \u22120.80), 3.8 (95% CI 3.4\u20134.2) and 1.8\u00a0mL\/s (95% CI 1.1\u20132.4) respectively, in favour of the combination group. The difference in PVR was not significant. There were no serious adverse events (AEs). The dropout rate due to AEs was 2.85%. Myalgia (five patients) was the commonest AE in the combination group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The combination of tamsulosin and tadalafil produced significantly better improvements in LUTS, QoL, erectile function and Q\n                      <jats:sub>max<\/jats:sub>\n                      compared to monotherapy with tamsulosin, without an increase in AEs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15027","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T13:58:06Z","timestamp":1580738286000},"page":"718-724","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double\u2010blinded, randomised controlled trial"],"prefix":"10.1111","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-3899","authenticated-orcid":false,"given":"Santhosh","family":"Nagasubramanian","sequence":"first","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal Thampi","family":"John","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belavendra","family":"Antonisamy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv Paul","family":"Mukha","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra Singh","family":"Jeyachandra Berry","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Devasia","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin Sudhakar","family":"Kekre","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Christian Medical College Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900622"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.08.015"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06609.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20999"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.09.006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.033"},{"key":"e_1_2_7_8_1","unstructured":"Professionals S\u2010O.EAU Guidelines: Management of Non\u2010neurogenic Male LUTS [Internet]. Uroweb. Available at:https:\/\/uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/#5. Accessed August 2019"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000142687.75577.e4"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000146906.42375.D3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12499"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12357"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09687.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02504.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.08.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.07.508"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13357"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.08.072"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02821.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00754.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12251"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.09.093"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.09.057"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0484-z"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.11.014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13489"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2453-x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-012-0317-7"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)56333-8"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10066"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.10.074"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01109.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.01.001"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.040"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2164\/jandrol.111.013185"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.05.005"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12722"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.11.094"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66780-6"},{"key":"e_1_2_7_40_1","first-page":"28","article-title":"Effect of tadalafil that was additionally administered to patients receiving an alpha1\u2010blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"107","author":"Hayashi K","year":"2016","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.04.012"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13744"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.15027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:43:25Z","timestamp":1761752605000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/bju.15027"],"URL":"https:\/\/doi.org\/10.1111\/bju.15027","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2020-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}